Merck (MRK) ended the recent trading session at $117.17, demonstrating a -0.05% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.19%.

Daiichi Sankyo and Merck said on Tuesday that their drug, patritumab deruxtecan, met the main goal of extending the time some ...

A phase 3 trial of Daiichi Sankyo and Merck & Co.’s HER3-directed antibody-drug conjugate (ADC) has hit its primary endpoint, ...

Kelemen et al. find that leveraging related traits improves polygenic score performance for abdominal aortic aneurysm. Health-economic modelling suggests that combining smoking and genetic risk ...

An academic partnership to improve diversity in clinical trials has drafted its first industry team members. | An academic ...

Merck ($MRK) continues to solidify its position in cancer treatment as its top-selling drug Keytruda delivers outstanding ...

Merck & Co.’s best-selling drug Keytruda helped women with a hard-to-treat form of breast cancer live longer, according to ...

In 2021, the FDA blasted Merck for using a premature endpoint to pursue a Keytruda approval in early-stage triple-negative ...

Along with breast cancer, cervical cancer is among the most feared cancer diagnoses for women around the world.

Even for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment ...